Virpax Historical Financial Ratios
| VRPX Stock | USD 0.46 0.02 4.17% |
Virpax Pharmaceuticals is promptly reporting on over 73 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0, PTB Ratio of 2.03 or Days Sales Outstanding of 0.0 will help investors to properly organize and evaluate Virpax Pharmaceuticals financial condition quickly.
Virpax |
About Virpax Financial Ratios Analysis
Virpax PharmaceuticalsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Virpax Pharmaceuticals investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Virpax financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Virpax Pharmaceuticals history.
Virpax Pharmaceuticals Financial Ratios Chart
Add Fundamental
Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Inventory Turnover
A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.Income Quality
An assessment of the sustainability of a company's earnings over time, considering factors like revenue source diversification and cost structure.Most ratios from Virpax Pharmaceuticals' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Virpax Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Virpax Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more information on how to buy Virpax Stock please use our How to Invest in Virpax Pharmaceuticals guide.At this time, Virpax Pharmaceuticals' PTB Ratio is fairly stable compared to the past year. PB Ratio is likely to rise to 2.03 in 2024, whereas Book Value Per Share is likely to drop 1.57 in 2024.
Virpax Pharmaceuticals fundamentals Correlations
Click cells to compare fundamentals
Virpax Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Virpax Pharmaceuticals fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Ptb Ratio | (12.46) | (7.66) | 1.07 | 0.44 | 1.94 | 2.03 | |
| Book Value Per Share | (5.24) | (8.53) | 32.0 | 14.16 | 1.65 | 1.57 | |
| Free Cash Flow Yield | (0.0332) | (0.0429) | (0.36) | (2.45) | (2.63) | (2.5) | |
| Operating Cash Flow Per Share | (2.17) | (2.8) | (12.41) | (15.24) | (8.41) | (8.83) | |
| Pb Ratio | (12.46) | (7.66) | 1.07 | 0.44 | 1.94 | 2.03 | |
| Free Cash Flow Per Share | (2.17) | (2.8) | (12.41) | (15.24) | (8.41) | (8.83) | |
| Roic | 2.25 | 1.64 | (0.32) | (1.31) | (8.11) | (7.71) | |
| Net Income Per Share | (6.58) | (9.07) | (10.37) | (18.32) | (12.97) | (13.62) | |
| Cash Per Share | 0.0796 | 0.11 | 31.45 | 16.22 | 7.81 | 7.42 | |
| Pocfratio | (30.09) | (23.32) | (2.76) | (0.41) | (0.38) | (0.4) | |
| Pfcf Ratio | (30.09) | (23.32) | (2.76) | (0.41) | (0.38) | (0.4) | |
| Income Quality | 0.34 | 0.32 | 1.21 | 0.82 | 0.65 | 0.54 | |
| Roe | 1.26 | 1.06 | (0.32) | (1.29) | (7.85) | (7.46) | |
| Ev To Operating Cash Flow | (31.17) | (24.41) | (0.23) | 0.66 | 0.55 | 0.57 | |
| Pe Ratio | (9.93) | (7.2) | (3.31) | (0.34) | (0.25) | (0.26) | |
| Return On Tangible Assets | (73.44) | (9.64) | (0.31) | (1.09) | (1.58) | (1.66) | |
| Ev To Free Cash Flow | (31.17) | (24.41) | (0.23) | 0.66 | 0.55 | 0.57 | |
| Earnings Yield | (0.1) | (0.14) | (0.3) | (2.95) | (4.05) | (3.85) | |
| Current Ratio | 0.0168 | 0.02 | 18.96 | 6.36 | 1.25 | 1.19 | |
| Tangible Book Value Per Share | (5.24) | (8.53) | 32.0 | 14.16 | 1.65 | 1.57 | |
| Graham Number | 27.85 | 41.72 | 86.41 | 76.39 | 21.95 | 34.14 | |
| Shareholders Equity Per Share | (5.24) | (8.53) | 32.0 | 14.16 | 1.65 | 1.57 | |
| Graham Net Net | (5.24) | (9.36) | 29.67 | 13.58 | 1.24 | 1.17 | |
| Price Earnings Ratio | (9.93) | (7.2) | (3.31) | (0.34) | (0.25) | (0.26) | |
| Price Book Value Ratio | (12.46) | (7.66) | 1.07 | 0.44 | 1.94 | 2.03 | |
| Price To Operating Cash Flows Ratio | (30.09) | (23.32) | (2.76) | (0.41) | (0.38) | (0.4) | |
| Price To Free Cash Flows Ratio | (30.09) | (23.32) | (2.76) | (0.41) | (0.38) | (0.4) | |
| Ebt Per Ebit | 1.04 | 1.03 | 1.0 | 0.99 | 0.97 | 1.11 | |
| Effective Tax Rate | (0.0377) | (0.0341) | (0.007699) | 0.00898 | 0.0103 | 0.0108 | |
| Company Equity Multiplier | (0.0171) | (0.11) | 1.06 | 1.19 | 4.98 | 5.23 | |
| Return On Capital Employed | 1.16 | 1.31 | (0.32) | (1.32) | (8.11) | (7.71) | |
| Quick Ratio | 0.0156 | 0.02 | 18.96 | 6.36 | 1.25 | 1.19 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Virpax Stock Analysis
When running Virpax Pharmaceuticals' price analysis, check to measure Virpax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virpax Pharmaceuticals is operating at the current time. Most of Virpax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Virpax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virpax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Virpax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.